These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 53722)

  • 21. Serum triiodothyronine 7-15 years after fractionated low dose radioiodine therapy of thyrotoxicosis.
    Herrmann J; Schaps D; Rusche HJ; Berger M; Krüskemper HL; von zur Hühlen A; Hackenberg K; Reinwein D
    Clin Endocrinol (Oxf); 1975 Mar; 4(2):205-12. PubMed ID: 48437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onset age is associated with outcome of radioiodine therapy in Graves' disease.
    Yamashita Y; Yamane K; Tamura T; Okubo M; Kohno N
    Endocr J; 2004 Apr; 51(2):127-32. PubMed ID: 15118261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Striving for euthyroidism in radioiodine therapy of Graves' disease: a 12-year prospective, randomized, open-label blinded end point study.
    Chen DY; Schneider PF; Zhang XS; He ZM; Jing J; Chen TH
    Thyroid; 2011 Jun; 21(6):647-54. PubMed ID: 21563916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperthyroidism due to Graves-Basedow disease in a woman refractory to thyroid hormones.
    González Cabrera N; Kalic AK; Antón Miguel MÁ; Sierra Polo P; Vicente Vicente MÁ
    Endocrinol Nutr; 2012 Dec; 59(10):609-11. PubMed ID: 22425314
    [No Abstract]   [Full Text] [Related]  

  • 25. Graves' ophthalmopathy and 131I therapy.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
    Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose.
    Haase A; Bähre M; Lauer I; Meller B; Richter E
    Exp Clin Endocrinol Diabetes; 2000; 108(2):133-7. PubMed ID: 10826521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
    Burch HB; Solomon BL; Cooper DS; Ferguson P; Walpert N; Howard R
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Letter: Intentional radioiodine ablation in Graves' disease.
    Hamburger JI
    Lancet; 1976 Feb; 1(7957):492. PubMed ID: 55765
    [No Abstract]   [Full Text] [Related]  

  • 29. Hypothyroid symptoms following radioiodine therapy for Graves' disease.
    Anolik JR
    Clin Cornerstone; 2005; 7 Suppl 2():S25-7. PubMed ID: 16399243
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient hypothyroidism after iodine-131 treatment of Graves' disease.
    Gómez JM; Virgili N; Soler J; Fernández M; Montaña E
    Thyroidology; 1989 Dec; 1(3):149-52. PubMed ID: 2484879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents.
    Wood LC; Ingbar SH
    J Clin Invest; 1979 Nov; 64(5):1429-36. PubMed ID: 91625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
    Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
    Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
    Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standardized radioiodine therapy in Graves' disease: the persistent effect of thyroid weight and radioiodine uptake on outcome.
    de Bruin TW; Croon CD; de Klerk JM; van Isselt JW
    J Intern Med; 1994 Nov; 236(5):507-13. PubMed ID: 7964426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease.
    Santos RB; Romaldini JH; Ward LS
    Thyroid; 2004 Jul; 14(7):525-30. PubMed ID: 15307942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: yes or no?
    Bogazzi F; Martino E; Bartalena L
    J Endocrinol Invest; 2003 Feb; 26(2):174-6. PubMed ID: 12739747
    [No Abstract]   [Full Text] [Related]  

  • 38. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid gland suppressibility in patients treated with radioiodine for diffuse toxic goiter.
    Burgos FL; Micames C; Rivera JV
    Bol Asoc Med P R; 1983 Apr; 75(4):173-5. PubMed ID: 6575791
    [No Abstract]   [Full Text] [Related]  

  • 40. Incidence of hypothyroidism following small doses of 131I in the treatment of Graves' disease.
    McCullagh EP; Jelden GL; Rodriguez-Antunez A
    Ohio State Med J; 1976 Sep; 72(9):538-40. PubMed ID: 989600
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.